Business
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025\nAnnounced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough \nManagement to host a conference call and webcast today at 4:30 p.m. ET \nNEW HAVEN, Conn., May 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced financial results for the quarter ended March 31, 2025, and provided business updates. \n\n \n \n \n \n \n \n\n \n\"The RIVER data in patients with RCC demonstrated the clinical significance of Haduvio's centrally and peripherally acting mechanism and its potential across a broad range of chronic cough patients and cough counts,\" said Jennifer Good, President and CEO of Trevi Therapeutics. \"Building on that positive momentum, we look forward to the topline results from the Phase 2b CORAL trial expected this quarter for the treatment of IPF patients with chronic cough. Chronic cough is a significant burden to IPF patients and there are no approved therapies. Trevi is at a pivotal moment with promising data, a dedicated development team advancing trials, and a strong balance sheet to support the continued development of Haduvio.\"\nFirst Quarter 2025 Financial Results and Recent Business Highlights \nEnrollment was completed in February 2025 in the Phase 2b CORAL trial of Haduvio in chronic cough patients with IPF and the last patient last visit was completed in April 2025. Topline results for the CORAL trial remain on track for the second quarter of 2025.In March, Trevi announced positive topline results from its Phase 2a RIVER trial of Haduvio in patients with RCC (N=66). Haduvio met the primary endpoint with a statistically significant reduction in objective 24-hour cough frequency of 67% from baseline and 57% on a placebo-adjusted basis (p8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-...